Plasticd, thanks. Gray was, and is, a most interesting chap. A tad like the curates eggs at times. He has not retired and retains various business interests.
As for 1st line in HCC - a very long way to go. Remember the case reported was a one off, and not subject to clinical trials criteria.
A good news story for sure, but that is all it is until we get some data from the SARAH study. If the reported case was replicated on a large scale in the SARAH study, then SRX stock will go ballistic. May have to wait until around 2017 to find out. Lets get the MCC to 1st line first
Probably less than 3 weeks for the top line data, and this is the predicate of any real future for SRX, salvage treatment aside. Expect some volatility in the SP due to risk management.
Changed my sentiment to hold during this period.
SRX Price at posting:
$32.98 Sentiment: Hold Disclosure: Held
